αααααβααΎαBT3 β’ FRA
add
Lineage Cell Therapeutics Inc
0.84β¬
4 ααααααΆ, 11:00:17 PM ααααβααα +2 · EUR · FRA · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
αα·αααΈαα»α
0.84β¬
α
αααααααααααα
0.84β¬ - 0.84β¬
α
ααααααα½αααααΆαα
α»αααααα
0.33β¬ - 1.00β¬
ααΎαβαα»αβααΈααααΆα
230.64Β ααΆα USD
ααα ααα½αααΌαααααα
377.00
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
ααααααΆαααΈααααΆα
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
(USD) | ααΈααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
α
αααΌα | 1.50Β ααΆα | 4.02% |
α
αααΆαααααα·ααααα·ααΆα | 5.03Β ααΆα | -2.24% |
α
αααΌααα»ααα | -4.14Β ααΆα | 36.73% |
ααααΆααα
αααααα»ααα | -275.57 | 39.17% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | -0.02 | 50.00% |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | -6.34Β ααΆα | 2.24% |
α’ααααΆαααααααααΆαααααα·αααααΆα | β | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
(USD) | ααΈααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 47.90Β ααΆα | 9.82% |
ααααααααα»α | 111.75Β ααΆα | 3.01% |
ααΆαααα½ααα»αααααΌαααα»α | 34.10Β ααΆα | -9.06% |
ααΌαβααααα»α | 77.66Β ααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 228.36Β ααΆα | β |
ααααααααααΉαααααα
| 2.40 | β |
ααα
ααααααΎαααααα | -14.46% | β |
ααα
ααααααΎααΎααα»α | -20.40% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
(USD) | ααΈααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
α
αααΌααα»ααα | -4.14Β ααΆα | 36.73% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | -4.89Β ααΆα | 15.51% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | 1.90Β ααΆα | 5,107.89% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | 5.04Β ααΆα | -64.03% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | 1.99Β ααΆα | -75.55% |
ααα αΌαααΆα
αααααΆααααααα | -2.58Β ααΆα | 21.63% |
α’αααΈ
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineageβs programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
ααΆααααααΎαα‘αΎα
1990
αααααβαααααΆα
αα»ααααα·α
74